A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection

Sharavathi Guddehalli Parameswarappa, Katrin Reppe, Andreas Geissner, Petra Ménová, Subramanian Govindan, Adam D J Calow, Annette Wahlbrink, Markus W. Weishaupt, Bopanna Ponnappa Monnanda, Roland Lawrence Bell, Liise-anne Pirofski, Norbert Suttorp, Leif Erik Sander, Martin Witzenrath, Claney Lebev Pereira, Chakkumkal Anish, Peter H. Seeberger

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.

Original languageEnglish (US)
Pages (from-to)1407-1416
Number of pages10
JournalCell Chemical Biology
Volume23
Issue number11
DOIs
StatePublished - Nov 17 2016

Fingerprint

Conjugate Vaccines
Glycoconjugates
Streptococcus pneumoniae
Oligosaccharides
Polysaccharides
Vaccines
Infection
Immunity
Assays
Carrier Proteins
Pneumococcal Vaccines
Monoclonal Antibodies
Antibodies
Pneumonia
Serogroup
Serum

Keywords

  • Epitope mapping
  • Glycan arrays
  • Glycoconjugate vaccines
  • Opsonophagocytosis
  • Streptococcus pneumoniae
  • Synthetic glycans

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

Parameswarappa, S. G., Reppe, K., Geissner, A., Ménová, P., Govindan, S., Calow, A. D. J., ... Seeberger, P. H. (2016). A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. Cell Chemical Biology, 23(11), 1407-1416. https://doi.org/10.1016/j.chembiol.2016.09.016

A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. / Parameswarappa, Sharavathi Guddehalli; Reppe, Katrin; Geissner, Andreas; Ménová, Petra; Govindan, Subramanian; Calow, Adam D J; Wahlbrink, Annette; Weishaupt, Markus W.; Monnanda, Bopanna Ponnappa; Bell, Roland Lawrence; Pirofski, Liise-anne; Suttorp, Norbert; Sander, Leif Erik; Witzenrath, Martin; Pereira, Claney Lebev; Anish, Chakkumkal; Seeberger, Peter H.

In: Cell Chemical Biology, Vol. 23, No. 11, 17.11.2016, p. 1407-1416.

Research output: Contribution to journalArticle

Parameswarappa, SG, Reppe, K, Geissner, A, Ménová, P, Govindan, S, Calow, ADJ, Wahlbrink, A, Weishaupt, MW, Monnanda, BP, Bell, RL, Pirofski, L, Suttorp, N, Sander, LE, Witzenrath, M, Pereira, CL, Anish, C & Seeberger, PH 2016, 'A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection', Cell Chemical Biology, vol. 23, no. 11, pp. 1407-1416. https://doi.org/10.1016/j.chembiol.2016.09.016
Parameswarappa, Sharavathi Guddehalli ; Reppe, Katrin ; Geissner, Andreas ; Ménová, Petra ; Govindan, Subramanian ; Calow, Adam D J ; Wahlbrink, Annette ; Weishaupt, Markus W. ; Monnanda, Bopanna Ponnappa ; Bell, Roland Lawrence ; Pirofski, Liise-anne ; Suttorp, Norbert ; Sander, Leif Erik ; Witzenrath, Martin ; Pereira, Claney Lebev ; Anish, Chakkumkal ; Seeberger, Peter H. / A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. In: Cell Chemical Biology. 2016 ; Vol. 23, No. 11. pp. 1407-1416.
@article{b91f658bb157488fa7c829a24a127fe2,
title = "A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection",
abstract = "The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.",
keywords = "Epitope mapping, Glycan arrays, Glycoconjugate vaccines, Opsonophagocytosis, Streptococcus pneumoniae, Synthetic glycans",
author = "Parameswarappa, {Sharavathi Guddehalli} and Katrin Reppe and Andreas Geissner and Petra M{\'e}nov{\'a} and Subramanian Govindan and Calow, {Adam D J} and Annette Wahlbrink and Weishaupt, {Markus W.} and Monnanda, {Bopanna Ponnappa} and Bell, {Roland Lawrence} and Liise-anne Pirofski and Norbert Suttorp and Sander, {Leif Erik} and Martin Witzenrath and Pereira, {Claney Lebev} and Chakkumkal Anish and Seeberger, {Peter H.}",
year = "2016",
month = "11",
day = "17",
doi = "10.1016/j.chembiol.2016.09.016",
language = "English (US)",
volume = "23",
pages = "1407--1416",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection

AU - Parameswarappa, Sharavathi Guddehalli

AU - Reppe, Katrin

AU - Geissner, Andreas

AU - Ménová, Petra

AU - Govindan, Subramanian

AU - Calow, Adam D J

AU - Wahlbrink, Annette

AU - Weishaupt, Markus W.

AU - Monnanda, Bopanna Ponnappa

AU - Bell, Roland Lawrence

AU - Pirofski, Liise-anne

AU - Suttorp, Norbert

AU - Sander, Leif Erik

AU - Witzenrath, Martin

AU - Pereira, Claney Lebev

AU - Anish, Chakkumkal

AU - Seeberger, Peter H.

PY - 2016/11/17

Y1 - 2016/11/17

N2 - The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.

AB - The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197 carrier protein conjugate elicited protective immunity as evidenced by opsonophagocytosis assays and protection against pneumonia caused by ST3 in mice. Formulation of the defined protective lead candidate glycotope has to be further evaluated to elicit optimal long-term immunity.

KW - Epitope mapping

KW - Glycan arrays

KW - Glycoconjugate vaccines

KW - Opsonophagocytosis

KW - Streptococcus pneumoniae

KW - Synthetic glycans

UR - http://www.scopus.com/inward/record.url?scp=84995810838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995810838&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2016.09.016

DO - 10.1016/j.chembiol.2016.09.016

M3 - Article

C2 - 27818299

AN - SCOPUS:84995810838

VL - 23

SP - 1407

EP - 1416

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 11

ER -